EUVIMEDEUVIMED entdecken
Fallbericht

Advanced CYLD Cutaneous Syndrome ( CCS ) Treated With the Hedgehog Signaling Pathway Inhibitor Vismodegib Results in a Limited Clinical Response

Jeanette Kaae iD, Lise Mette Rahbek Gjerdrum, Tim Svenstrup Poulsen, Estrid Hoegdall iD, Gregor Borut Jemec

APMIS · 2025

DOI: 10.1111/apm.70104 ↗

Kurz gefasst

Fallbericht in der Zeitschrift APMIS, 2025. Verfasst von Jeanette Kaae und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Copenhagen University Hospital, Zealand University Hospital, Roskilde, Denmark. Hauptthemen laut MEDLINE: Anilides, Pyridines, Deubiquitinating Enzyme CYLD, Hedgehog Proteins. Die Arbeit nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CYLD Cutaneous syndrome (CCS) is a rare autosomal dominantly inherited disease associated with multiple nodular adnexal skin tumors, most commonly trichoepitheliomas and cylindromas. There is no evidence‐based treatment for this disease. This study aimed to present the histological response and to investigate whether molecular and immunohistochemical analyses (exome sequencing) may provide insight into the rapid disease development and lack of response to treatment with Vismodegib. A patient treated with the Hedgehog Pathway Inhibitor Vismodegib. The CYLD (c.1437_1438del, p.Pro480PhefsTer16) frameshift deletion was identified in the family of our patient. In addition, our patient also lost the unaffected allele and was consequently homozygous for the deletion. Treatment with Vimodegib was unfortunately not effective. Furthermore, we observed no possible biomarkers of progression and/or treatment response. Hopefully, further studies will contribute to the genetic understanding of BSS and identify patients at high risk of developing severe disease, thereby supporting the stratification of patients who will benefit from early surgical treatment or treatment with Vismodegib.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnilidesPyridinesDeubiquitinating Enzyme CYLDHedgehog ProteinsNeoplastic Syndromes, HereditarySkin NeoplasmsAntineoplastic AgentsHumansSignal TransductionMaleFemaleMiddle AgedTreatment OutcomePedigreeAdultExome Sequencing

Stichwörter der Autor:innen

Brooke‐Spieglers syndromehedgehog signaling pathway inhibitorskin diseases

Substanzen

AnilidesHhAntag691PyridinesDeubiquitinating Enzyme CYLDHedgehog ProteinsCYLD protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Dermatology, Copenhagen University Hospital, Zealand University Hospital, Roskilde, Denmark.
  • Department of Pathology, Copenhagen University Hospital, Zealand University Hospital, Roskilde, Denmark.
  • Department of Pathology, Copenhagen University Hospital, Herlev and Gentofte University Hospital, Copenhagen, Denmark.

ORCID-Profile: Jeanette Kaae, Estrid Hoegdall

Zitieren

APA

Kaae, J., Gjerdrum, L. M. R., Poulsen, T. S., Hoegdall, E., & Jemec, G. B. (2025). Advanced CYLD Cutaneous Syndrome ( CCS ) Treated With the Hedgehog Signaling Pathway Inhibitor Vismodegib Results in a Limited Clinical Response. APMIS. https://doi.org/10.1111/apm.70104

Vancouver

Kaae J, Gjerdrum LMR, Poulsen TS, Hoegdall E, Jemec GB. Advanced CYLD Cutaneous Syndrome ( CCS ) Treated With the Hedgehog Signaling Pathway Inhibitor Vismodegib Results in a Limited Clinical Response. APMIS. 2025. doi:10.1111/apm.70104

BibTeX
@article{Kaae2025,
  author = {Kaae, Jeanette and Gjerdrum, Lise Mette Rahbek and Poulsen, Tim Svenstrup and Hoegdall, Estrid and Jemec, Gregor Borut},
  title = {Advanced CYLD Cutaneous Syndrome ( CCS ) Treated With the Hedgehog Signaling Pathway Inhibitor Vismodegib Results in a Limited Clinical Response},
  journal = {APMIS},
  year = {2025},
  doi = {10.1111/apm.70104}
}
Kostenlos starten →